Back to Search Start Over

L-Arginine Improves Solubility and ANTI SARS-CoV-2 Mpro Activity of Rutin but Not the Antiviral Activity in Cells

Authors :
Fundación hna
Instituto de Investigación Sanitaria Aragón
Instituto de Salud Carlos III
European Commission
Ministerio de Economía y Competitividad (España)
Diputación General de Aragón
Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España)
Ministry of Science and Higher Education (Poland)
Sancineto, Luca [0000-0002-6199-7399]
Ostacolo, Carmine[0000-0003-3715-8680]
Ortega-Alarcon, David [0000-0003-1885-4365]
Ceballos-Laita, Laura [0000-0002-7223-1719]
Abian, Olga [0000-0001-5664-1729]
Velázquez-Campoy, Adrián [0000-0001-5702-4538]
Moretti, Silvia [0000-0002-8177-7254]
Dabrowska, Agnieszka [0000-0003-1499-4950]
Botwina, Pawel [0000-0001-9006-1568]
Synowiec, Aleksandra [0000-0001-9846-6922]
Kula-Pacurar, Anna [0000-0001-8404-2176]
Pyrc, Krzysztof [0000-0002-3867-7688]
Iraci, Nunzio [0000-0002-1359-8684]
Santi, Claudio [0000-0002-7698-8970]
Sancineto, Luca
Ostacolo, Carmine
Ortega-Alarcón, David
Jiménez-Alesanco, Ana
Ceballos-Laita, Laura
Vega, Sonia
Abian, Olga
Velázquez-Campoy, Adrián
Moretti, Silvia
Dabrowska, Agnieszka
Botwina, Pawel
Synowiec, Aleksandra
Kula-Pacurar, Anna
Pyrc, Krzysztof
Iraci, Nunzio
Santi, Claudio
Fundación hna
Instituto de Investigación Sanitaria Aragón
Instituto de Salud Carlos III
European Commission
Ministerio de Economía y Competitividad (España)
Diputación General de Aragón
Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España)
Ministry of Science and Higher Education (Poland)
Sancineto, Luca [0000-0002-6199-7399]
Ostacolo, Carmine[0000-0003-3715-8680]
Ortega-Alarcon, David [0000-0003-1885-4365]
Ceballos-Laita, Laura [0000-0002-7223-1719]
Abian, Olga [0000-0001-5664-1729]
Velázquez-Campoy, Adrián [0000-0001-5702-4538]
Moretti, Silvia [0000-0002-8177-7254]
Dabrowska, Agnieszka [0000-0003-1499-4950]
Botwina, Pawel [0000-0001-9006-1568]
Synowiec, Aleksandra [0000-0001-9846-6922]
Kula-Pacurar, Anna [0000-0001-8404-2176]
Pyrc, Krzysztof [0000-0002-3867-7688]
Iraci, Nunzio [0000-0002-1359-8684]
Santi, Claudio [0000-0002-7698-8970]
Sancineto, Luca
Ostacolo, Carmine
Ortega-Alarcón, David
Jiménez-Alesanco, Ana
Ceballos-Laita, Laura
Vega, Sonia
Abian, Olga
Velázquez-Campoy, Adrián
Moretti, Silvia
Dabrowska, Agnieszka
Botwina, Pawel
Synowiec, Aleksandra
Kula-Pacurar, Anna
Pyrc, Krzysztof
Iraci, Nunzio
Santi, Claudio
Publication Year :
2021

Abstract

The COVID-19 pandemic outbreak prompts an urgent need for efficient therapeutics, and repurposing of known drugs has been extensively used in an attempt to get to anti-SARS-CoV-2 agents in the shortest possible time. The glycoside rutin shows manifold pharmacological activities and, despite its use being limited by its poor solubility in water, it is the active principle of many pharmaceutical preparations. We herein report our in silico and experimental investigations of rutin as a SARS-CoV-2 Mpro inhibitor and of its water solubility improvement obtained by mixing it with l-arginine. Tests of the rutin/l-arginine mixture in a cellular model of SARS-CoV-2 infection highlighted that the mixture still suffers from unfavorable pharmacokinetic properties, but nonetheless, the results of this study suggest that rutin might be a good starting point for hit optimization.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1293835399
Document Type :
Electronic Resource